Jason B. Gibbons, PhD

Articles by Jason B. Gibbons, PhD

Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib

ByJason B. Gibbons, PhD,Charles L. Bennett, MD, PhD, MPP,Kenneth R. Carson, MD,Gerard F. Anderson, PhD

April 2nd 2024

Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.

Humira: The First $20 Billion Drug

ByJason B. Gibbons, PhD,Micaela Laber, MPH, MBA,Charles L. Bennett, MD, PhD, MPP

February 8th 2023

The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.

Small Practice Participation and Performance in Medicare Accountable Care Organizations

ByJason B. Gibbons, PhD,Chiang-Hua Chang, PhD,Mousumi Banerjee, PhD,Jennifer Meddings, MD, MSc,Edward C. Norton, PhD,Lena Chen, MD, MS,Julie P.W. Bynum, MD, MPH

March 11th 2022

Medicare beneficiaries attributed to small practices in accountable care organizations (ACOs) achieve greater savings than beneficiaries attributed to large practices in ACOs.